Seres Therapeutics (MCRB) Return on Equity (2016 - 2025)
Seres Therapeutics' Return on Equity history spans 11 years, with the latest figure at 3.35% for Q2 2025.
- For Q2 2025, Return on Equity rose 137.0% year-over-year to 3.35%; the TTM value through Jun 2025 reached 3.35%, up 137.0%, while the annual FY2024 figure was 8.1%, 362.0% down from the prior year.
- Return on Equity for Q2 2025 was 3.35% at Seres Therapeutics, down from 4.14% in the prior quarter.
- Across five years, Return on Equity topped out at 10.68% in Q1 2023 and bottomed at 8.67% in Q3 2023.
- The 5-year median for Return on Equity is 0.14% (2021), against an average of 0.94%.
- The largest annual shift saw Return on Equity surged 1149bps in 2023 before it tumbled -895bps in 2024.
- A 5-year view of Return on Equity shows it stood at 0.42% in 2021, then crashed by -1011bps to 4.67% in 2022, then surged by 211bps to 5.17% in 2023, then increased by 29bps to 6.68% in 2024, then plummeted by -50bps to 3.35% in 2025.
- Per Business Quant, the three most recent readings for MCRB's Return on Equity are 3.35% (Q2 2025), 4.14% (Q1 2025), and 6.68% (Q4 2024).